SANA — Sana Biotechnology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1770121 ·
Last close
$1.88
Market Cap
$563.31M
52W High
$5.49
52W Low
$1.84
ADV30
2,946,839
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | 18,506,000 | 20,401,000 | 376,127,000 | 41,104,000 | 195,763,000 |
| Jun 2026 | 0 | — | -65,420,000 | -63,635,000 | 431,522,000 | 57,073,000 | 276,954,000 |
| Mar 2026 | 0 | — | -48,614,000 | -47,210,000 | 373,593,000 | 83,800,000 | 254,353,000 |
| Dec 2025 | 0 | — | -61,199,000 | -58,825,000 | 416,890,000 | 71,870,000 | 256,006,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,239,000
Investing CF
$-102,603,000
Financing CF
$220,644,000
CapEx
$-2,823,000
Dividends Paid
—
Buybacks
$-60,000
EPS Diluted TTM
$-0.76
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,959,861,000
Inventory
—
Receivables
—
ST Investments
$103,417,000
EBIT TTM
$-218,748,000
Pretax Income TTM
$-211,822,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -205,708,000 | -244,166,000 | 416,890,000 | 256,006,000 | 160,884,000 | -143,828,000 |
| Dec 2024 | 0 | -270,832,000 | -266,759,000 | 501,020,000 | 250,516,000 | 250,504,000 | -223,153,000 |
| Dec 2023 | 0 | -286,127,000 | -283,255,000 | 565,299,000 | 277,793,000 | 287,506,000 | -253,582,000 |
| Dec 2022 | 0 | -272,564,000 | -269,476,000 | 822,720,000 | 323,405,000 | 499,315,000 | -290,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-211,822,000
OpCashFlow TTM
—
Assets (Latest)
$431,522,000
Forward EPS
$-0.56
Max Pain — expiry 2027-01-15
max pain strike: $2.00 · spot: $1.85 · call oi: 3,439 · put oi: 1,194
Expected Move to 2027-01-15:
±$1.15
(62.16%) —
implied range
$0.70 –
$3.00
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRZN | Surrozen, Inc./DE | $571.47M | $29.98 | — |
| VALN | Valneva SE | $527.69M | $5.57 | — |
| CGEM | Cullinan Therapeutics, Inc. | $602.14M | $9.27 | — |
| ETRA | Electra Therapeutics, Inc. | $524.10M | $8.35 | — |
| ENTX | Entera Bio Ltd. | $521.77M | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
Bears are Losing Control Over Sana (SANA), Here's Why It's a 'Buy' Now
2026-11-16 13:55 · Yahoo
Sana: Q3 Earnings Snapshot
2026-11-05 23:01 · Yahoo
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-05 21:05 · Yahoo
Sana Biotechnology to Present at September 2026 Investor Conferences
2026-09-01 20:05 · Yahoo
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM
2026-07-16 21:11 · Yahoo
Sana (SANA) Upgraded to Buy: Here's What You Should Know
2026-07-15 16:00 · Yahoo
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
2026-07-01 13:00 · Yahoo
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
2026-04-27 06:22 · Yahoo
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
2026-05-05 20:05 · Yahoo
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
2026-04-27 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.